血尿是接受静脉血栓栓塞 (VTE) 抗凝治疗的前列腺癌患者的常见并发症。早期识别高危患者可能有助于降低其发生率和严重程度。我们使用 RIETE 登记处的数据来制定 VTE 抗凝治疗第一年血尿的预后评分。使用回归系数建立预后评分。从2001年3月到2021年3月，招募了1934名患有前列腺癌和急性VTE的患者。其中，1034 例 (53%) 最初表现为肺栓塞，900 例 (47%) 最初表现为孤立性深静脉血栓 (DVT)。在抗凝期间（中位 181 天；四分位数范围：97-354），99 名患者 (5.1%) 出现血尿（致命 1 例，严重 27 例，非严重 72 例）。发生率为：每 100 患者年发生 8 起事件 (95% CI 6.5-9.7)。出现血尿的中位时间为 53 天 (IQR 4-134)。在多变量分析中，近期血尿、初始表现为 DVT、合并症、转移、血红蛋白水平 <11 g/dL、肌酐 >1.2 mg/dL 和放射治疗独立预测血尿风险。 C 统计值为 0.71（95% CI：0.65-0.77）。 ≥1.5 分的截止点将 312 名患者 (20%) 归类为高危，具有最高的敏感性 (51%; 95%CI: 39-62) 和特异性 (82%; 95%CI: 79-83) 。我们的分数提高了 RIETE 分数（c 统计量：0.61；95%CI：0.54-0.68；NRI：0.09）或 VTE-BLEED 分数（c 统计量：0.64；NRI：0.09）的表现和非事件净重分类指数 (NRI)。 95%CI：0.58-0.71；NRI：0.76）。前列腺癌患者抗凝 VTE 期间血尿的预后评分表现良好，与其他经过验证的评分相比，识别率得到了提高。版权所有 © 2023 Elsevier Ltd。保留所有权利。

Haematuria is a common complication in prostate cancer patients receiving anticoagulation for venous thromboembolism (VTE). Early identification of at-risk patients might help to reduce its incidence and severity.We used data from the RIETE registry to develop a prognostic score for haematuria during the first year of anticoagulation for VTE. The prognostic score was built using regression coefficients.From March 2001 through March 2021, 1934 patients with prostate cancer and acute VTE were enrolled. Of these, 1034 (53 %) initially presented as pulmonary embolism and 900 (47 %) as isolated deep vein thrombosis (DVT). During anticoagulation (median 181 days; inter-quartile range: 97-354), 99 patients (5.1 %) developed haematuria (fatal 1, major 27, non-major 72). The incidence rate was: 8 events per 100 patient-years (95%CI 6.5-9.7). Median time to haematuria was 53 days (IQR 4-134). On multivariable analysis, recent haematuria, initial presentation as DVT, comorbidity, metastases, haemoglobin levels <11 g/dL, creatinine >1.2 mg/dL, and radiotherapy independently predicted the risk for haematuria. C-statistics was 0.71 (95%CI: 0.65-0.77). A cut-off of ≥1.5 points classified 312 patients (20 %) at high-risk and had the highest sensitivity (51 %; 95%CI: 39-62) and specificity (82 %; 95%CI: 79-83). Our score improved the performance and non-event net reclassification index (NRI) of the RIETE score (c-statistics: 0.61; 95%CI: 0.54-0.68; NRI: 0.09) or VTE-BLEED score (c-statistics: 0.64; 95%CI: 0.58-0.71; NRI: 0.76).A prognostic score for haematuria during anticoagulation for VTE performed well in patients with prostate cancer, and improved identification compared to other validated scores.Copyright © 2023 Elsevier Ltd. All rights reserved.